Presentation Archives - WuXi Biology

Drug-Resistant KRAS G12D Lung Cancer Models

KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge. Understanding how that resistance develops is critical...

In Vivo CAR-T Preclinical Evaluation Platform

CAR-T therapies have transformed the treatment of hematologic malignancies, yet complex manufacturing, long production timelines, and high costs continue to...

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...

Stress Model for Antidepressant Drug Discovery

Stress is a major environmental risk factor that triggers depressive episodes, inducing symptoms such as anhedonia, negative cognitive bias, and...

KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...

Induced Pruritus Model in NHP

The “itch-scratch cycle” is a central pathogenic driver in many pruritic (itch-related) inflammatory skin diseases, such as atopic dermatitis (AD),...

Spontaneous Mouse Tumor-derived Syngeneic Models

Spontaneous mouse tumor-derived syngeneic models are valuable tools in preclinical cancer research. These tumor models offer unique advantages because immunotherapies...

PBMC Humanized Tumor Models for Evaluating T-cell Engagers

T-cell engagers (TCEs) are a class of bispecific antibody-based immunotherapies designed to bring T cells into close proximity with cancer...

Combination Therapies in a Mouse MASH Model

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a serious liver disease. If left untreated, MASH can...

Knowledge Library